News MSD gets first FDA okay for oral PCSK9 cholesterol drug MSD has won the race to bring an oral PCSK9 inhibitor through to regulatory approval for LDL cholesterol-lowering in the US.
News Daiichi teams up with GAIA for cholesterol DTx in Europe Daiichi Sankyo has licensed European rights to GAIA's digital therapeutic for people with high cholesterol, currently in phase 3 testing.
News LIB takes aim at cholesterol market with new PCSK9 option LIB Therapeutics has won FDA approval for a once-monthly cholesterol drug, Lerochol, that it says offers ease-of-use advantages over rivals.
News AHA: MSD's oral PCSK9 matches injectables MSD closes on filing for enlicitide, a PCSK9 inhibitor that could offer the efficacy of injectables with the ease of a once-daily pill.
News MSD, Ionis trumpet lipid-lowering drug data MSD's enlicitide scores in hypercholesterolaemia, as Ionis lines up broader use for recent approval Tryngolza in severe hypertriglyceridaemia.
News Update: Rumour confirmed as Lilly buys Verve Therapeutics Ahead of an opt-in decision on a PCSK9 inhibitor candidate, Eli Lilly is reported to be in advanced takeover negotiations with Verve Therapeutics.
News Lundbeck preps for key bexicaserin data around year-end Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth hopes.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
